Drugs / RBL001
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02035956 | Dec 2013 → Feb 2017 | melanoma | BioNTech RNA Pharmaceuticals GmbH | Completed | No outcome recorded |
| Phase 1 | NCT01684241 | Jun 2012 → May 2015 | melanoma | BioNTech RNA Pharmaceuticals GmbH | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RBL001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01684241 ↗ |
| Modality | Vaccine | “RBL001/RBL002 are naked ribonucleic acid (RNA) based recombinant vaccines that were optimized to induce antigen specific CD8+ and CD4+ T cell responses against malignant...” NCT01684241 ↗ |
| Route | Other | “intranodal administrations of RBL001 and RBL002” NCT01684241 ↗ |